|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 295/145 | (2006.01) |
| C07B 59/00 | (2006.01) | ||
| A61K 51/04 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 4095130 |
| (13) | Kind of document | T |
| (96) | European patent application number | 22178736.9 |
| Date of filing the European patent application | 2014-10-17 | |
| (97) | Date of publication of the European application | 2022-11-30 |
| (45) | Date of publication and mention of the grant of the patent | 2024-01-31 |
| (46) | Date of publication of the claims translation | 2024-04-25 |
| (30) | Number | Date | Country code |
| 13004991 | 2013-10-18 | EP | |
| 14175612 | 2014-07-03 | EP |
| (72) |
EDER, Matthias , DE
KOPKA, Klaus , DE
SCHÄFER, Martin , DE
BAUDER-WÜST, Ulrike , DE
HABERKORN, Uwe , DE
BENESOVA, Martina , DE
MIER, Walter , DE
KLIEM, Hans-Christian , DE
KRATOCHWIL, Clemens , DE
EISENHUT, Michael , DE
|
| (73) |
Novartis AG ,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Žymėti prostatos specifinio membranos antigeno (PSMA) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER |
| Payment date | Validity (years) | Amount | |
| 2024-09-19 | 11 | 289.00 EUR |
| 2025-10-17 |